174 related articles for article (PubMed ID: 12939544)
1. [Pharmacological action and clinical aspects of salmeterol].
Oguri K
Nihon Yakurigaku Zasshi; 2003 Sep; 122(3):265-70. PubMed ID: 12939544
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease.
Cazzola M; Centanni S; Boveri B; Di Marco F; Santus P; Matera MG; Allegra L
Respiration; 2001; 68(5):452-9. PubMed ID: 11694805
[TBL] [Abstract][Full Text] [Related]
3. Salmeterol: a novel, long-acting beta 2-agonist.
Meyer JM; Wenzel CL; Kradjan WA
Ann Pharmacother; 1993 Dec; 27(12):1478-87. PubMed ID: 7905757
[TBL] [Abstract][Full Text] [Related]
4. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
[TBL] [Abstract][Full Text] [Related]
5. Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids.
Nelson HS; Nathan RA; Kalberg C; Yancey SW; Rickard KA
MedGenMed; 2001 Jul; 3(4):3. PubMed ID: 11549982
[TBL] [Abstract][Full Text] [Related]
6. Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.
Brogden RN; Faulds D
Drugs; 1991 Nov; 42(5):895-912. PubMed ID: 1723379
[TBL] [Abstract][Full Text] [Related]
7. Salmeterol: a long-acting beta 2-agonist.
D'Alonzo GE; Tolep K
J Am Osteopath Assoc; 1998 Apr; 98(4):216-8, 221-31. PubMed ID: 9594486
[TBL] [Abstract][Full Text] [Related]
8. Salmeterol: an inhaled beta 2-agonist with prolonged duration of action.
Lötvall J; Svedmyr N
Lung; 1993; 171(5):249-64. PubMed ID: 8105155
[TBL] [Abstract][Full Text] [Related]
9. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
Aaron SD; Vandemheen KL; Fergusson D; Maltais F; Bourbeau J; Goldstein R; Balter M; O'Donnell D; McIvor A; Sharma S; Bishop G; Anthony J; Cowie R; Field S; Hirsch A; Hernandez P; Rivington R; Road J; Hoffstein V; Hodder R; Marciniuk D; McCormack D; Fox G; Cox G; Prins HB; Ford G; Bleskie D; Doucette S; Mayers I; Chapman K; Zamel N; FitzGerald M;
Ann Intern Med; 2007 Apr; 146(8):545-55. PubMed ID: 17310045
[TBL] [Abstract][Full Text] [Related]
10. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma.
Busse W; Nelson H; Wolfe J; Kalberg C; Yancey SW; Rickard KA
J Allergy Clin Immunol; 1999 Jun; 103(6):1075-80. PubMed ID: 10359889
[TBL] [Abstract][Full Text] [Related]
11. Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease.
Nannini L; Lasserson TJ; Poole P
Cochrane Database Syst Rev; 2003; (4):CD003794. PubMed ID: 14583994
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
13. [Long-acting beta(2)-adrenoceptor agonists for asthma and COPD].
Rabe KF; Ukena D; Magnussen H
Med Klin (Munich); 1997 Dec; 92 Suppl 5():44-9. PubMed ID: 19479397
[TBL] [Abstract][Full Text] [Related]
14. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.
Rennard SI; Anderson W; ZuWallack R; Broughton J; Bailey W; Friedman M; Wisniewski M; Rickard K
Am J Respir Crit Care Med; 2001 Apr; 163(5):1087-92. PubMed ID: 11316640
[TBL] [Abstract][Full Text] [Related]
15. Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients.
Cazzola M; Mantero A; Santus P; Carlucci P; Mondoni M; Bosotti L; Centanni S
Pulm Pharmacol Ther; 2007; 20(3):258-64. PubMed ID: 16600647
[TBL] [Abstract][Full Text] [Related]
16. Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.
Brogden RN; Faulds D
Allergol Immunopathol (Madr); 1992; 20(2):72-84. PubMed ID: 1359777
[TBL] [Abstract][Full Text] [Related]
17. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.
Welsh EJ; Cates CJ; Poole P
Cochrane Database Syst Rev; 2010 May; (5):CD007891. PubMed ID: 20464758
[TBL] [Abstract][Full Text] [Related]
18. Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol.
Basu K; Palmer CN; Tavendale R; Lipworth BJ; Mukhopadhyay S
J Allergy Clin Immunol; 2009 Dec; 124(6):1188-94.e3. PubMed ID: 19800676
[TBL] [Abstract][Full Text] [Related]
19. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
Jarvis B; Markham A
Drugs Aging; 2001; 18(6):441-72. PubMed ID: 11419918
[TBL] [Abstract][Full Text] [Related]
20. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy.
Fish JE; Israel E; Murray JJ; Emmett A; Boone R; Yancey SW; Rickard KA
Chest; 2001 Aug; 120(2):423-30. PubMed ID: 11502639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
